Klaria Secures Over 75% of Rights Offering and Bridge Financing
Pharmaceutical company Klaria has secured subscription and underwriting commitments for approximately 75.3 percent of its rights offering and obtained SEK 30.7 million in bridge financing. The company is also preparing for an extraordinary general meeting in October.
Klaria Pharma Holding AB has secured subscription and underwriting commitments equivalent to approximately 75.3 percent of its upcoming rights offering. Additionally, the company announced it has obtained bridge financing totaling approximately SEK 30.7 million.
These developments precede an extraordinary general meeting scheduled for October 5, 2026. The meeting's agenda includes resolutions concerning the company's financial matters.
The bridge financing is intended to support Klaria's operations and liquidity until the rights offering is fully completed. Klaria is focused on the development of pharmaceutical treatments, particularly for pain and migraine.
Further details regarding the specific use of proceeds from the rights offering have not been disclosed, though the company has previously indicated a need for funding for its research and development activities.